AbCellera Reports Q2 2026 Business Results

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions Saved Articles My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire AbCellera Reports Q2 2026 Business ResultsAuthor of the article: You can save this article by registering for free here. Or sign-in if you have an account.VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an Account“Last quarter we completed enrollment for the Phase 2 study of ABCL635, and we expect to announce top-line data very soon,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “Since our last business update we signed two new collaborations, one with Jazz and one with Vertex, that leverage our T-cell engager platform to advance programs into the clinic and are adding over $100 million in upfront cash to our balance sheet.”Q2 2026 Business Summary and Program UpdatesGet the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againABCL635 top-line data readout from the Phase 2 trial expected in August 2026.ABCL386 and ABCL688 are progressing through IND-enabling activities.Announced collaboration with Jazz Pharmaceuticals plc to discover and develop next-generation T-cell engagers (TCEs) for multiple gastrointestinal cancers and other solid tumors. AbCellera is receiving $84 million in total upfront payments, with $56 million for the first two research programs and $28 million for a third program, which will initiate within 12 months. AbCellera is eligible to receive up to $792 million per program in option fees and development, regulatory, and commercial sales milestone payments along with tiered royalties on net sales ranging from mid-single digits to low double digits.Completed dosing for the Phase 1 study of ABCL575, with top-line data readout expected in Q4 2026.Announced the appointments of Dr. Victor Sandor and Dr. Lynn Seely as independent directors to AbCellera’s board of directors.Generated a net loss of $55.4 million, compared to a net loss of $34.7 million in Q2 2025.Ended the quarter with over $565 million in total cash balances and marketable securities, providing over $675 million in total available liquidity to execute on AbCellera’s strategy.On July 29, 2026 announced a collaboration with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific TCEs for autoimmune diseases and other conditions. AbCellera will receive $28 million in total upfront payments and is eligible to receive preclinical, development, regulatory, and commercial milestone payments, along with tiered royalties on net sales.Discussion of Q2 2026 Financial ResultsRevenue – Total revenue was $4.1 million, compared to $17.1 million in Q2 2025.Research & Development (R&D) Expenses – R&D expenses were $46.0 million, compared to $39.2 million in Q2 2025.Sales, General, & Administrative (SG&A) Expenses – SG&A expenses were $13.9 million, compared to $22.0 million in Q2 2025.Net Loss – Net loss of $55.4 million, or $(0.18) per share on a basic and diluted basis, compared to net loss of $34.7 million, or $(0.12) per share on a basic and diluted basis, in Q2 2025.Available Liquidity – over $565 million in total cash balances and marketable securities, and $110 million in available non-dilutive government funding, bringing total available liquidity to over $675 million to execute on AbCellera’s strategy.At the end of Q2 2026, partners led 35 programs that AbCellera believes to be progressing and where AbCellera holds a downstream stake (down from 44 on December 31, 2025). In total, AbCellera held downstream stakes in 12 molecules in the clinic understood to be progressing on June 30, 2026.Conference Call and Webcastwill host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.About AbCellera Biologics Inc(Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For more information, please visitAbCellera Forward-Looking StatementsThis document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, plans, objectives for future operations, and the evaluation of our available liquidity to execute on our strategy (including our ability to access our reimbursement based R&D government contributions). The use of certain data derived from cross-study comparisons are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities and differences and are presented for informational purposes. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.This advertisement has not loaded yet.This advertisement has not loaded yet, but your article continues below.These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.AbCellera Biologics Inc. Condensed Consolidated Statements of Loss and Comprehensive Loss (All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data.) (Unaudited)Three months ended June 30,Six months ended June 30,2025202620252026Revenue:Research fees$6,639$3,901$10,707$12,021Licensing and royalty revenue10,44514910,613341Total revenue17,0844,05021,32012,362Operating expenses:Research and development(1)39,21345,98781,71192,649Sales, general, and administrative(1)21,98613,85041,05426,185Depreciation and amortization5,4706,99010,80113,828Total operating expenses66,66966,827133,566132,662Loss from operations(49,585)(62,777)(112,246)(120,300)Other (income) expense:Interest and other(9,549)42(15,073)(3,606)Grants and incentives(3,692)(3,854)(7,845)(8,193)Total other income(13,241)(3,812)(22,918)(11,799)Loss before income tax(36,344)(58,965)(89,328)(108,501)Income tax recovery(1,617)(3,538)(8,980)(9,909)Net loss$(34,727)$(55,427)$(80,348)$(98,592)Foreign currency translation adjustment4,341(733)1,7211,082Comprehensive loss$(30,386)$(56,160)$(78,627)$(97,510)Net loss per shareBasic$(0.12)$(0.18)$(0.27)$(0.32)Diluted$(0.12)$(0.18)$(0.27)$(0.32)Weighted-average common shares outstandingBasic298,508,601305,557,294298,105,760304,329,623Diluted298,508,601305,557,294298,105,760304,329,623(1) Exclusive of depreciation and amortizationAbCellera Biologics Inc. Condensed Consolidated Balance Sheets (All figures in U.S. dollars. Amounts are expressed in thousands except share data.) (Unaudited)December 31, 2025June 30, 2026AssetsCurrent assets:Cash and cash equivalents$128,513$120,065Marketable securities405,313420,039Total cash, cash equivalents, and marketable securities533,826540,104Accounts and accrued receivable58,29318,597Restricted cash25,00025,000Other current assets111,11395,529Total current assets728,232679,230Long-term assets:Property and equipment, net428,003416,677Intangible assets, net38,38136,530Goodwill47,80647,806Investments in equity accounted investees62,58065,229Other long-term assets51,94862,103Total long-term assets628,718628,345Total assets$1,356,950$1,307,575Liabilities and shareholders’ equityCurrent liabilities:Accounts payable and other current liabilities$50,781$32,484Deferred revenue13,52620,705Total current liabilities64,30753,189Long-term liabilities:Operating lease liability137,403129,948Deferred revenue3,50040,450Deferred government contributions174,453178,254Other long-term liabilities10,3839,714Total long-term liabilities325,739358,366Total liabilities390,046411,555Commitments and contingenciesShareholders’ equity:Common shares: no par value, unlimited authorized shares at December 31, 2025 and June 30, 2026: 300,600,710 and 306,469,632 shares issued and outstanding at December 31, 2025 and June 30, 2026, respectively802,341821,242Additional paid-in capital198,279206,004Accumulated other comprehensive loss(4,234)(3,152)Accumulated deficit(29,482)(128,074)Total shareholders’ equity966,904896,020Total liabilities and shareholders’ equity$1,356,950$1,307,575AbCellera Biologics Inc. Condensed Consolidated Statement of Cash Flows (Expressed in thousands of U.S. dollars.) (Unaudited)Six months ended June 30,20252026Cash flows from operating activities:Net loss$(80,348)$(98,592)Cash flows from operating activities:Depreciation of property and equipment8,95111,977Amortization of intangible assets1,8511,851Amortization of operating lease right-of-use assets2,8633,610Stock-based compensation28,99324,299Other707,019Changes in operating assets and liabilities:Research fees and grants receivable(12,524)25,367Income taxes receivable(7,588)(8,024)Accounts payable and accrued liabilities(7,356)(16,621)Deferred revenue9,36144,129Deferred grant income(1,681)(4,453)Other assets13,4501,838Net cash used in operating activities(43,958)(7,600)Cash flows from investing activities:Purchases of property and equipment(24,001)(5,963)Purchase of marketable securities(291,542)(308,184)Proceeds from marketable securities303,437293,557Receipt of grant funding6,4486,955Long-term investments and other assets(18,218)(105)Net cash used in investing activities(23,876)(13,740)Cash flows from financing activities:Proceeds from deferred government contributions and other2,59513,585Net cash provided by financing activities2,59513,585Effect of exchange rate changes on cash and cash equivalents1,351(468)Decrease in cash and cash equivalents(63,888)(8,223)Cash and cash equivalents and restricted cash, beginning of period183,615155,249Cash and cash equivalents and restricted cash, end of period$119,727$147,026Restricted cash included in other assets2,2901,961Total cash, cash equivalents, and restricted cash shown on the balance sheet$117,437$145,065Supplemental disclosure of non-cash investing and financing activitiesProperty and equipment in accounts payable12,733979Right-of-use assets obtained in exchange for operating lease obligation69,787–View source version on businesswire.com: Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774 Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005 Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.